RE: Facts Not Fiction - Goodbye Fat Frog29 Jun 2022 13:30
This post is specifically for @Iceman888, you asked for one thing hope this post helps.
Firstly, no doubt Suzy is feeling like a one-legged woman in an ars@ kicking contest, the abuse frankly has been unreal and shame on those involved but some are looking for a blame game and I guess the buck stops with her.
It is not an easy job being CEO, it’s a thankless task at times. We also really need to appreciate how dire the markets have been during here tenure, we have covid, a war, a collapse of the Bio Index, falling markets and recently stocks in the sector either crashing like SNG or AVCT or collapsing like the recent debacle over at 4D. So, it’s not been great conditions has it…
Despite this Specifically relating to Suzy here are some highlights: -
*Cleared up the mess created by the last lot. Including changing contract terms on pipeline drugs so they can be positioned.
*Brought all costs under control. They now run a tight ship. A bootstrap business that makes a pound go a long way. This is a radical change.
*Changed the direction of the business, they now have specific focus in Women’s Oncology rather than a scatter gun approach.
*Additions to the pipeline including: -
Evaluation Agreement Uni Barcelona (Spain) - Treatment of KRAS
Evaluation Agreement Uni Hokkaido (Japan) - Endometrial, Pancreatic and Bile Duct Cancers
Evaluation Agreement Uni (London) - Triple Negative Breast Cancer
Negotiated New and Extended Collaboration Agreement with Physiomics plc
*Further looking for revenue generation outside of licensing. Acquisition and Creation of a lab will support that.
*Working to complete deals or close off the legacy drugs. 201 oks not the deal we wanted but maybe it was the only way that it could be dealt with.
*Significant DD work on 201 to help position it, this is a MAJOR job, don't underestimate how challenging this is, not least updating patents, re-negotiated and re-stated the CRT licence for 201 ostensibly to allow the TheoremRx deal go ahead and 201 being "Investment ready", and by splitting out the oncology and non-oncology licenses, but also updating the terms throughout.
*Radical overhaul of IR. A fantastic open channel of communication with shareholders possibly one of the best on the AIM index. I think everyone agrees how much better this is.
*Massive improvement in Trust, We trust her, she cares and is passionate about this business being a success - this also counts for a lot. Its not longer a business to feed fat cats, she has changed it.
But its bigger than this, a complete change of direction and change of attitude in the business top down and she has only been in situ 24 mths in the role. Not long.
We have all identified she needs support, I’m not advocating she is perfect, but we have the making of something great here, a few additions get the current situation under control and drive it forwards from here. I have every confidence she can do it and the SP will ultimately bounce back.
GLA